CLARUS THERAPEUTICS HOLDINGS (CRXT)

US18271L1070 - Common Stock

0.099  -0.06 (-36.94%)

After market: 0.101 +0 (+2.02%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
6.369M13.957M
119.14%		19.32M
38.43%
EBITDA
YoY % growth
-47.159M
-163.87%		-39.707M
15.80%		-49.572M
-24.84%
EBIT
YoY % growth
-47.177M
-163.91%		-39.732M
15.78%		-36.733M
7.55%
Operating Margin
-740.73%-284.67%-190.13%
EPS
YoY % growth
N/AN/A-1.02

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q3 / 22 Q4 / 22
EPS
Q2Q % growth		-0.22
14.58%
Revenue
Q2Q % growth		6.013M
40.30%
EBITDA
Q2Q % growth		-11.73M
EBIT
Q2Q % growth		-9.773M
-15.89%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2022
Q2Q % growth		 -0.21 -0.290.0828.20%
Q1 2022
Q2Q % growth		 -0.61 -0.41-0.20-47.66%
Q4 2021
Q2Q % growth		 -0.19 -0.690.5072.61%
Q3 2021
Q2Q % growth		 -0.26 -0.820.5668.44%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2022
Q2Q % growth		 4.05M
-20.73%		5.199M-1.149M-22.10%
Q1 2022
Q2Q % growth		 4.011M
72.15%		5.61M-1.599M-28.50%
Q4 2021
Q2Q % growth		 4.562M
88.05%		4.733M-170.8K-3.61%
Q3 2021
Q2Q % growth		 4.286M
92.72%		3.235M1.051M32.50%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A